CN1516582A - 抗病毒化合物 - Google Patents
抗病毒化合物 Download PDFInfo
- Publication number
- CN1516582A CN1516582A CNA028099044A CN02809904A CN1516582A CN 1516582 A CN1516582 A CN 1516582A CN A028099044 A CNA028099044 A CN A028099044A CN 02809904 A CN02809904 A CN 02809904A CN 1516582 A CN1516582 A CN 1516582A
- Authority
- CN
- China
- Prior art keywords
- virus
- ester
- halogen
- octahydro
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
化合物 | IC50(μM) | 平均IC50(μM)±SD | CC50(μM) |
Bucast | 10,10,20,25 | 16.25±7.5 | >1000 |
栗籽豆精胺 | 180,190,280 | 216.6±55.0 | >1000 |
N-丁基-DNJ | >300,250 | >300 | |
N-壬基-DNJ | 90,120 | 105 | 毒性@300 |
化合物 | *IC50(μM) | CC50(μM) |
Bucast | 60,30,70,40,60平均=52±16.43 | >300 |
栗籽豆精胺 | 300,500平均=400 | >1000 |
N-丁基-DNJ | >300,>1000 | >1000 |
N-壬基-DNJ | 60,>100 | 120 |
MOI | IC50(μM) | |
Bucast | N-丁基-DNJ | |
0.1 | 200,170 | >300 |
0.01 | 60,30 | >300 |
0.001 | 40 | >300 |
0.0001 | 5.0 | 55 |
固定药物浓度 | IC50 | 组合指数(CI) |
干扰素α(IRU/孔) | Bucast(uM) | |
0.5 | 3 | 0.46 |
0.25 | 4 | 0.28 |
0.125 | 13 | 0.37 |
0 | 52±16.43 | |
Bucast(μM) | 干扰素α(IRU/孔) | |
10 | 0.12 | 0.3 |
5 | 0.22 | 0.28 |
0 | 1.3 |
Claims (26)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0110832.3A GB0110832D0 (en) | 2001-05-03 | 2001-05-03 | Antiviral compounds |
GB0110832.3 | 2001-05-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1516582A true CN1516582A (zh) | 2004-07-28 |
CN100428936C CN100428936C (zh) | 2008-10-29 |
Family
ID=9913938
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB028099044A Expired - Lifetime CN100428936C (zh) | 2001-05-03 | 2002-05-02 | 抗病毒化合物 |
Country Status (20)
Country | Link |
---|---|
US (1) | US7601735B2 (zh) |
EP (1) | EP1387681B1 (zh) |
JP (2) | JP2004527566A (zh) |
KR (1) | KR100660241B1 (zh) |
CN (1) | CN100428936C (zh) |
AT (1) | ATE405261T1 (zh) |
AU (1) | AU2002341155B2 (zh) |
CA (1) | CA2445271A1 (zh) |
CY (1) | CY1110437T1 (zh) |
DE (1) | DE60228436D1 (zh) |
DK (1) | DK1387681T3 (zh) |
ES (1) | ES2312587T3 (zh) |
GB (1) | GB0110832D0 (zh) |
HK (1) | HK1068538A1 (zh) |
IL (2) | IL158558A0 (zh) |
NO (1) | NO326292B1 (zh) |
NZ (1) | NZ529448A (zh) |
PT (1) | PT1387681E (zh) |
WO (1) | WO2002089780A2 (zh) |
ZA (1) | ZA200308483B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102343083A (zh) * | 2011-10-17 | 2012-02-08 | 中国科学院成都生物研究所 | 一种抗病毒的组合药物 |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0116643D0 (en) * | 2001-07-09 | 2001-08-29 | Virogen Ltd | Antiviral compounds |
GB0500020D0 (en) | 2005-01-04 | 2005-02-09 | Novartis Ag | Organic compounds |
WO2006085141A2 (en) * | 2004-08-13 | 2006-08-17 | Migenix Inc. | Compositions and methods for treating or preventing hepadnaviridae infection |
EA200700718A1 (ru) * | 2004-10-06 | 2007-12-28 | Мидженикс Инк. | Комбинированные противовирусные композиции, содержащие кастаноспермин, и способы их применения |
US20060194835A1 (en) * | 2005-02-09 | 2006-08-31 | Migenix Inc. | Compositions and methods for treating or preventing flaviviridae infections |
JP2007297289A (ja) * | 2006-04-27 | 2007-11-15 | Kitasato Gakuen | 抗ウイルス剤 |
CA2666814A1 (en) * | 2006-08-21 | 2008-05-29 | United Therapeutics Corporation | Combination therapy for treatment of viral infections |
KR101314166B1 (ko) * | 2011-06-16 | 2013-10-04 | 건국대학교 산학협력단 | 석이버섯 가수분해 효소 추출물 또는 이로로부터 분리된 화합물을 유효성분으로 함유하는 항산화 조성물 |
GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
MY170991A (en) | 2013-03-15 | 2019-09-23 | 60? Pharmaceuticals Llc | Dosing regimens of celgosivir for the treatment of dengue |
AP2016009157A0 (en) * | 2013-09-27 | 2016-04-30 | Merck Sharp & Dohme | Substituted quinolizine derivatives useful as hiv integrase inhibitors |
US10046005B2 (en) * | 2014-02-07 | 2018-08-14 | Shaker A. Mousa | Composition and method of use for combinations of anti-viral protease, polymerase inhibitors and natural bioactive compounds in the treatment of hepatitis C infection |
JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
WO2017100505A1 (en) * | 2015-12-11 | 2017-06-15 | 60° Pharmaceuticals Llc | Novel dosing regimens of celgosivir for the prevention of dengue |
WO2017167953A1 (en) | 2016-03-31 | 2017-10-05 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
WO2017167950A1 (en) | 2016-03-31 | 2017-10-05 | Janssen Pharmaceuticals, Inc. | Substituted indole derivatives as dengue viral replication inhibitors |
JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
EA201892200A1 (ru) | 2016-04-01 | 2019-03-29 | Янссен Фармасьютикалз, Инк. | Замещенные производные соединений индола в качестве ингибиторов репликации вирусов денге |
JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
BR112019024311A2 (pt) | 2017-05-22 | 2020-07-28 | Janssen Pharmaceuticals, Inc. | derivados de indolina substituídos como inibidores da replicação viral do dengue |
PE20200604A1 (es) | 2017-05-22 | 2020-03-10 | Janssen Pharmaceuticals Inc | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue |
JP7497790B2 (ja) * | 2019-12-27 | 2024-06-11 | 国立大学法人北海道大学 | 豚コレラの治療及び/又は予防剤 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1315276C (en) | 1987-07-02 | 1993-03-30 | Paul S. Liu | Castanospermine esters and glycosides |
US5004746A (en) | 1987-09-29 | 1991-04-02 | Merrell Dow Pharmaceuticals Inc. | Anti-retroviral castanospermine esters |
US4849430A (en) | 1988-03-09 | 1989-07-18 | Monsanto Company | Method of inhibiting virus |
US5017563A (en) * | 1988-06-23 | 1991-05-21 | Merrell Dow Pharmaceuticals Inc. | Castanospermine esters and glycosides |
US4970317A (en) | 1989-08-08 | 1990-11-13 | Merrell Dow Pharmaceuticals Inc. | Process for the preparation of castanospermine esters |
US5093501A (en) | 1990-03-12 | 1992-03-03 | Merrell Dow Pharmaceuticals Inc. | Intermediates in a process for the preparation of castanospermine |
US5066807A (en) | 1990-03-12 | 1991-11-19 | Merrell Dow Pharmaceuticals Inc. | Process for the preparation of castanospermine |
GB9027433D0 (en) | 1990-12-18 | 1991-02-06 | Merrell Dow Pharma | Anti-herpes castanospermine esters |
US5939430A (en) * | 1993-02-22 | 1999-08-17 | Merrell Pharmaceuticals Inc. | Combinations of retroviral inhibitors |
GB9719189D0 (en) * | 1997-09-09 | 1997-11-12 | Glaxo Group Ltd | New therapeutic method |
US5959111A (en) | 1997-05-22 | 1999-09-28 | Hoechst Marion Roussel, Inc. | Process for preparing 6-0-monoesters of castanospermine |
AU761748B2 (en) | 1997-12-11 | 2003-06-12 | Chancellor, Masters And Scholars Of The University Of Oxford, The | Inhibition of membrane-associated viral replication |
AU2001234596A1 (en) * | 2000-01-28 | 2001-08-07 | Timothy M Block | Use of castanospermine and substituted-castanospermine compounds for treating hepatitis virus infections |
-
2001
- 2001-05-03 GB GBGB0110832.3A patent/GB0110832D0/en not_active Ceased
-
2002
- 2002-05-02 KR KR1020037014319A patent/KR100660241B1/ko not_active IP Right Cessation
- 2002-05-02 DE DE60228436T patent/DE60228436D1/de not_active Expired - Lifetime
- 2002-05-02 PT PT02742947T patent/PT1387681E/pt unknown
- 2002-05-02 NZ NZ529448A patent/NZ529448A/en not_active IP Right Cessation
- 2002-05-02 AU AU2002341155A patent/AU2002341155B2/en not_active Expired
- 2002-05-02 ES ES02742947T patent/ES2312587T3/es not_active Expired - Lifetime
- 2002-05-02 AT AT02742947T patent/ATE405261T1/de active
- 2002-05-02 DK DK02742947T patent/DK1387681T3/da active
- 2002-05-02 IL IL15855802A patent/IL158558A0/xx active IP Right Grant
- 2002-05-02 JP JP2002586917A patent/JP2004527566A/ja not_active Ceased
- 2002-05-02 CN CNB028099044A patent/CN100428936C/zh not_active Expired - Lifetime
- 2002-05-02 US US10/475,830 patent/US7601735B2/en active Active
- 2002-05-02 EP EP02742947A patent/EP1387681B1/en not_active Expired - Lifetime
- 2002-05-02 CA CA002445271A patent/CA2445271A1/en not_active Abandoned
- 2002-05-02 WO PCT/EP2002/004944 patent/WO2002089780A2/en active IP Right Grant
-
2003
- 2003-10-23 IL IL158558A patent/IL158558A/en unknown
- 2003-10-30 ZA ZA200308483A patent/ZA200308483B/en unknown
- 2003-10-31 NO NO20034878A patent/NO326292B1/no not_active IP Right Cessation
-
2005
- 2005-01-27 HK HK05100700.6A patent/HK1068538A1/xx not_active IP Right Cessation
- 2005-06-01 JP JP2005161641A patent/JP4406383B2/ja not_active Expired - Lifetime
-
2008
- 2008-11-19 CY CY20081101328T patent/CY1110437T1/el unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102343083A (zh) * | 2011-10-17 | 2012-02-08 | 中国科学院成都生物研究所 | 一种抗病毒的组合药物 |
Also Published As
Publication number | Publication date |
---|---|
JP2005290015A (ja) | 2005-10-20 |
AU2002341155B2 (en) | 2007-10-18 |
PT1387681E (pt) | 2008-12-02 |
DK1387681T3 (da) | 2009-01-05 |
GB0110832D0 (en) | 2001-06-27 |
KR100660241B1 (ko) | 2006-12-20 |
WO2002089780A3 (en) | 2003-03-06 |
JP4406383B2 (ja) | 2010-01-27 |
JP2004527566A (ja) | 2004-09-09 |
HK1068538A1 (en) | 2005-04-29 |
US7601735B2 (en) | 2009-10-13 |
ES2312587T3 (es) | 2009-03-01 |
IL158558A (en) | 2011-09-27 |
KR20040007527A (ko) | 2004-01-24 |
NO20034878L (no) | 2003-12-22 |
US20040147549A1 (en) | 2004-07-29 |
ATE405261T1 (de) | 2008-09-15 |
EP1387681A2 (en) | 2004-02-11 |
DE60228436D1 (de) | 2008-10-02 |
CY1110437T1 (el) | 2015-04-29 |
NO20034878D0 (no) | 2003-10-31 |
ZA200308483B (en) | 2005-10-26 |
EP1387681B1 (en) | 2008-08-20 |
WO2002089780A2 (en) | 2002-11-14 |
CN100428936C (zh) | 2008-10-29 |
IL158558A0 (en) | 2004-05-12 |
NO326292B1 (no) | 2008-11-03 |
NZ529448A (en) | 2005-11-25 |
CA2445271A1 (en) | 2002-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1516582A (zh) | 抗病毒化合物 | |
CN103209703B (zh) | 大环脯氨酸衍生的hcv丝氨酸蛋白酶抑制剂 | |
JP5902698B2 (ja) | ポリメラーゼの阻害のための方法および組成物 | |
TW200412960A (en) | Potent inhibitor of HCV serine protease | |
CN1324212A (zh) | 治疗或预防病毒感染及有关疾病的方法 | |
JP2010070566A (ja) | ウイルス性肝炎の処置 | |
US20080075695A1 (en) | Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein | |
CN101035555A (zh) | 包含栗精胺的组合抗病毒组合物及其使用方法 | |
CN1582146A (zh) | 用非多肽环-磷酸腺苷水平调节剂诱导排卵的方法 | |
CN1162149C (zh) | 用于预防或治疗病毒性心肌炎的医药组合物 | |
TW201121958A (en) | Methods of treating hepatitis C virus with oxoacetamide compounds | |
KR102597757B1 (ko) | 천연물 유래 화합물 및 이를 유효성분으로 함유하는 항바이러스제 | |
CN1342156A (zh) | 用赛菊宁黄质及其类似物抑制和治疗乙型肝炎病毒和黄病毒 | |
CN1278178A (zh) | 大环内酯类在治疗癌症和黄斑变性中的应用 | |
CN103889963B (zh) | 喹唑啉酮类似物以及喹唑啉酮类似物在用于治疗或预防某些病毒感染中的应用 | |
CN1251993A (zh) | N-取代的1,5-二脱氧-1,5-亚氨基-d-山梨醇化合物在治疗肝炎病毒感染的联合疗法中的用途 | |
JPH0232093A (ja) | 抗レトロウィルスジフルオロ化ヌクレオシド類 | |
JP2023534723A (ja) | コロナウイルス感染症の治療におけるベンフルメトール及びその誘導体の応用 | |
IL237119A (en) | Heterocyclic carboxamides for the treatment of viral diseases | |
CN1140992A (zh) | 用作抗病毒剂的黄素衍生物 | |
JP2015526504A (ja) | Hcvの大環状プロテアーゼ阻害剤と、非ヌクレオシドhcv阻害剤と、リトナビルとの組み合わせ | |
CN107998400B (zh) | 一种药物组合物及其在制备治疗黄病毒属病毒感染的药物中的应用 | |
EP2614144B1 (en) | Use of inhibitors of phospholipase a2 for the treatment or prevention of flavivirus infection | |
CN1822841A (zh) | 抗冠状病毒剂 | |
DE602004010291T2 (de) | Hcv-hemmende sulfonamide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1068538 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1068538 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: SANOFI SYNTHELABO Free format text: FORMER OWNER: VIROGEN LTD. Effective date: 20120912 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: SANOFI Free format text: FORMER NAME: SANOFI SYNTHELABO |
|
CP01 | Change in the name or title of a patent holder |
Address after: Paris France Patentee after: Sanofi Address before: Paris France Patentee before: SANOFI-AVENTIS |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120912 Address after: Paris France Patentee after: SANOFI-AVENTIS Address before: London, England Patentee before: Virogen Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20081029 |
|
CX01 | Expiry of patent term |